Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

Diabetes Care

Volumn 28, Issue 8, 2005, Pages 1936-1940

  Ahrén, Bo ^a   Pacini, Giovanni ^b   Foley, James E ^c   Schweizer, Anja ^c  

^a LUND UNIVERSITY   (Sweden)

^b CNR   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; INSULIN; METFORMIN; PLACEBO; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INHIBITION KINETICS; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TEST MEAL;

ADAMANTANE; ANTIGENS, CD26; AREA UNDER CURVE; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; METFORMIN; MIDDLE AGED; PLACEBOS; PROTEASE INHIBITORS;

EID: 23044487247     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.8.1936     Document Type: Article

References (24)

1. Mentlein R: Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 85:9-24, 1999
2. Hoist JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol 287:E199-E206, 2004
3. Deacon CF, Ahrén B, Holst JJ: Inhibitors of dipeptidyl peptidase IV: a novel approach to prevention and treatment of type 2 diabetes. Expert Opin Investig Drugs 13:1091-1102, 2004
4. Pedersen RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Dermuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucinethiazolidide. Diabetes 47:1253-1258, 1998
5. Balkan B, Kwasnik L, Miserendino R, Hoist JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42: 1324-1331, 1999
6. Kvist Reimer M, Holst JJ, Ahrén B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727, 2002
7. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875, 2002
8. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metal 89:2078-2084, 2004
9. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880, 2004
10. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE: 1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789, 2003
11. Ahren B, Pacini G: Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies (Review). Eur J Endocrinol 150:97-104, 2004
12. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ: A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24: 539-548, 2001
13. Ahren B, Pacini G: Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. Am J Physiol 273:E701-E707, 1997
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
15. Ludvik B, Waldhäusl W, Prager R, Kautzky-Willer A, Pacini G: Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patients. Metabolism 52:875-880, 2003
16. Kautzky-Willer A, Krssak M, Winzer C, Pacini G, Tura A, Farhan S, Wagner O, Brabant G, Horn R, Stingl H, Schneider B, Waldhausl W, Roden M: Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes. Diabetes 52:245-251, 2003
17. Rask E, Olsson T, Söderberg S, Holst JJ, Tura A, Pacini G, Ahrén B: Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 53:624-631, 2004
18. Kanauchi M, Yamano S, Kanauchi K, Saito Y: Homeostasis model assessment of insulin resistance, quantitative insulin sensitivity check index, and oral glucose insulin sensitivity index in nonobese non-diabetic subjects with high-normal blood pressure J Clin Endocrinol Metab 88:3444-3446, 2003
19. Ørskov L, Holst JJ, Moller J, Ørskov C, Moller N, Alberti KG, Schmilz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232, 1996
20. Ahrén B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
21. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
22. Pospisilik JA, Stafford SG, Demuth Hul, McIntosh CHS, Pederson RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic- hyperinsulinemic clamp study. Diabetes 51:2677-2683, 2003
23. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man. J Gin Invest 68: 1456-1467, 1981
24. Kahn SE, Prigeon ERL, McCulloch DK, EJ Boyko, RN Bergman, MW Schwartz, JL Neifmg, WK Ward, JC Beard, JP Palmer, et al.: Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993